Clinical trials: Glabellar Lines
Glabellar Rhytides
Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.
- Trial name
- NCT01814670
- Testing
- botulinum toxin Type A
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Allergan
Glabellar Lines
To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.
To compare the safety and efficacy of "HG-102" with Botox® in the improvement of moderate to severe glabellar lines.
- Trial name
- NCT04944953
- Testing
- Botulinum Toxin Type A Injection [Botox], Botulinum toxin type A injection [HG-102]
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Hugel
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL)…
- Trial name
- NCT04259086
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 8 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines
Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines
To evaluate the efficacy and safety of HG102 for moderate to severe Glabellar Lines, non-inferiority compared to Botox® was confirmed and safety was evaluated.
- Trial name
- NCT05801146
- Testing
- Botulinum Toxin Type A Injection [HG102], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 272 people
- Sponsor
- Hugel
Glabellar Frown Lines
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.
- Trial name
- NCT05481931
- Testing
- prabotulinumtoxinA
- Where
- Germany
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.
- Trial name
- NCT04157686
- Testing
- MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2
- Where
- 38 sites in United States, Belgium and 4 more
- Volunteers
- 957 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
- Trial name
- NCT04830345
- Testing
- ATGC-100 100U, Botox 100U
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Glabellar Lines
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT06205797
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to assess the effectiveness and safety of Corabotase (also known as IPN10200) compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants.
- Trial name
- LAURITE 1 (NCT07427797)
- Testing
- Corabotase
- Where
- 23 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Ipsen
Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar…
- Trial name
- NCT02236312
- Testing
- Botulinum Toxin Type A
- Where
- 8 sites in United States
- Volunteers
- 359 people
- Sponsor
- Galderma R&D
Moderate to Severe Glabellar Lines
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06151561
- Testing
- AGN-151586
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AbbVie
Glabellar Lines
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
The objective of this study is to demonstrate the efficacy of Dysport for the improvement in appearance of moderate to severe glabellar lines and to assess the short term and long term safety of Dysport, used for the improvement…
- Trial name
- NCT02450526
- Testing
- Botulinum toxin type A
- Where
- 10 sites in China
- Volunteers
- 520 people
- Sponsor
- Ipsen
Rhytids in the Glabellar Region
Efficacy Trial for the Reduction of Glabellar Lines
The purpose of this study is to evaluate the ability of the Serene RF System to effectively improve the appearance of dynamic glabellar lines and sustain the effect for a minimum of 3 months.
- Trial name
- NCT02466178
- Testing
- Serene RF System
- Where
- 5 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Serene Medical Inc
Glabellar Frown Lines
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT04281745
- Testing
- CORETOX Inj
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a…
- Trial name
- NCT05364580
- Testing
- PROTOXIN, Botox®
- Where
- 5 sites in South Korea
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Lines
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
A Randomized, Double-blind, Active-controlled, Multi-center Phase 3 Trial to Investigate the Efficacy and Safety of CKDB-501A in Subjects with Moderated-to-severe Glabella Lines
- Trial name
- NCT05804656
- Testing
- CKDB-501A, Botox®
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- CKD Bio Corporation
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to find out about the effectiveness and safety of a single dose of corabotase (also known as IPN10200) compared to placebo works in participants with moderate to severe glabellar lines.
- Trial name
- LAURITE 3 (NCT07779252)
- Testing
- Corabotase
- Where
- 9 sites in China
- Volunteers
- 160 people
- Sponsor
- Ipsen